Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Aiming at \100 Billion Sales in 2005: Mr Ogawa of Nippon Roche
January 29, 2001
- Most Patients Satisfied with Administration Method for Zithromac
January 29, 2001
- Schering-Plough, Shionogi to Comarket Antiallergic Claritin
January 29, 2001
- Phase III Comparative Study on Progressive Lung Cancer Begins
January 29, 2001
- Toho Ties Up with Tsuruhara Yoshii in Kumamoto
January 29, 2001
- Overall Mortality Increases at Total Cholesterol of 180 mg/dl or Less
January 29, 2001
- Santen Agrees with Nippon Organon to Develop, Manufacture, Market Glaucoma Treatment
January 29, 2001
- Novartis 5-Generation Campaign Recruits 378 Families
January 29, 2001
- Sankyo Completes Purchase of Sankyo Parke Davis Stocks from Pfizer
January 29, 2001
- WHO GLs for Allergic Rhinitis Introduced at UCB Symposium
January 29, 2001
- Kuraya Sanseido Aims at Sales of \1.5 Trillion in Next Stage
January 29, 2001
- BI Establishes Virtual Research Institute of Aging
January 29, 2001
- EMA Dissatisfied with FPMAJ Policy Regarding Healthcare Reform
January 29, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
January 29, 2001
- Yoshitomiyakuhin to Increase Market Share for Antipsychotic Drugs
January 29, 2001
- Major Analysts See Matsumotokiyoshi as No. 1 Drugstore Chain Operator
January 29, 2001
- BUSINESS NEWS IN BRIEF
January 29, 2001
- NHI Program Suffers from Ordinary Loss of \119 Bil. in 1999
January 29, 2001
- Tsuruha: Full-year Sales to Total \80.9 Bil.
January 29, 2001
- Fujirebio: Net Loss due to New Retirement Allowance Accounting
January 29, 2001
ページ
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…